Overactive bladder (OAB) is a common lower urinary tract disorder characterized by urgency, increased frequency, and, in some cases, urinary incontinence. Although antimuscarinic drugs (M-anticholinergics) or β3-adrenergic agonists as monotherapy provides relief to some patients, moderate treatment efficiency and tolerability often require drug switching (in case of side effects) or combination therapy (due to insufficient efficiency). The aim of this review was to analyze the combined use of mirabegron (β3-adrenergic agonist) and solifenacin (M-anticholinergic or muscarinic receptor antagonist), focusing on clinical trials, safety issues, and practical aspects. The combination therapy showed superior efficacy compared to monotherapy and an acceptable safety profile, making it a viable treatment strategy for patients with OAB who do not achieve optimal outcomes with a monotherapy.

Keywords: β3-adrenergic agonist, OAB, mirabegron, anticholinergics, solifenacin, combination therapy, treatment compliance, overactive bladder